Tag: 最終協議

ARCA Biopharmaceuticals (NASDAQ: ABIO) and Oruka Therapeutics, a privately held biotechnology company focused on the development of novel biologics for the treatment of chronic skin diseases, including plaque psoriasis, have entered into a definitive agreement to merge the two companies in an all-stock transaction. The merged entity will focus on advancing Oruka's product lines, including ORKA-001 (IL-23p19 inhibitor) and ORKA-002 (IL-17A/F inhibitor). Upon completion of the synergies, the synergized company plans to o